Mutua, G., Anzala, O., Luhn, K., Robinson, C., Bockstal, V., Anumendem, D., & Douoguih, M. (2019). Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. J Infect Dis.
Chicago Style CitationMutua, Gaudensia, Omu Anzala, Kerstin Luhn, Cynthia Robinson, Viki Bockstal, Dickson Anumendem, i Macaya Douoguih. "Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya." J Infect Dis 2019.
Cita MLAMutua, Gaudensia, et al. "Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya." J Infect Dis 2019.